Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending October 2014. The report serves as a notification of transactions involving Directors and Persons Discharging Managerial Responsibility (PDMRs) in accordance with DTR 3.1.4R(1)(a).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure of shareholding changes rather than a financial performance report.
Material Changes
The filing details increases in the notional interests of specific PDMRs in GSK Ordinary Shares. These increases resulted from the re-investment of dividends paid on shares held in the GlaxoSmithKline Deferred Investment Award Programme. The transactions occurred at a price of 1,412.25 pence per share.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items.
Important Facts for Investors
- Transaction Type: Dividend re-investment under the Deferred Investment Award Programme.
- Share Price: 1,412.25 pence per Ordinary Share.
- Participants: Mr R G Connor, Mr S A Hussain, Mr D S Redfern, Ms C Thomas, Dr P J T Vallance, Ms E Walmsley, and Mrs V A Whyte.
- Share Increases: Ranged from 104.950 shares (Mrs V A Whyte) to 859.185 shares (Ms E Walmsley).
- Reporting Date: October 6, 2014.